Cerebral perfusion imaging predicts levodopa-induced dyskinesia in Parkinsonian rat model.

Jarrad Perron, Sophia Krak, Samuel Booth, Dali Zhang, Ji Hyun Ko

Abstract read

In one paragraph

Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Cerebrospinal fluid dopamine 3-O-sulfate as a novel biomarker for predicting motor complications in Parkinson's disease: insights from the PPMI cohort.Journal of translational medicine · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jarrad PerronGraduate Program in Biomedical Engineering, Price Faculty of Engineering, University of Manitoba, 75 Chancellor's Circle, Winnipeg, MB, R3T 5V6, Canada.

Sophia KrakPrairieNeuro Research Centre, Kleysen Institute for Advanced Medicine, Health Sciences Centre, 710 William Avenue, Winnipeg, MB, R3E 3J7, Canada.

Samuel BoothPrairieNeuro Research Centre, Kleysen Institute for Advanced Medicine, Health Sciences Centre, 710 William Avenue, Winnipeg, MB, R3E 3J7, Canada.

Dali ZhangPrairieNeuro Research Centre, Kleysen Institute for Advanced Medicine, Health Sciences Centre, 710 William Avenue, Winnipeg, MB, R3E 3J7, Canada.

Ji Hyun KoGraduate Program in Biomedical Engineering, Price Faculty of Engineering, University of Manitoba, 75 Chancellor's Circle, Winnipeg, MB, R3T 5V6, Canada. ji.ko@umanitoba.ca.

Funding

Natural Sciences and Engineering Research Council of Canada CGS-D-579035-2023Natural Sciences and Engineering Research Council of Canada RGPIN-2016-05964Parkinson Canada GSA-2021-0000000065Research Manitoba 2009University of Manitoba 60473

6 · The paper itself

Abstract

Many Parkinson's disease (PD) patients manifest complications related to treatment called levodopa-induced dyskinesia (LID). Preventing the onset of LID is crucial to the management of PD, but the reasons why some patients develop LID are unclear. The ability to prognosticate predisposition to LID would be valuable for the investigation of mitigation strategies. Thirty rats received 6-hydroxydopamine to induce Parkinsonism-like behaviors before treatment with levodopa (2 mg/kg) daily for 22 days. Fourteen developed LID-like behaviors. Fluorodeoxyglucose PET, T

Identifiers

PMID41028738

DOI10.1038/s41531-025-01133-6

PMCPMC12485092

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.